Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19004480 | IMMUNOMODULATORY HYDROGEL AND PREPARATION METHOD THEREOF | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18889055 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | September 2024 | February 2025 | Allow | 5 | 0 | 0 | No | No |
| 18889023 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | September 2024 | December 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18889070 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | September 2024 | January 2025 | Allow | 4 | 0 | 0 | No | No |
| 18760757 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | July 2024 | June 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18758699 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | June 2024 | December 2024 | Allow | 6 | 1 | 0 | No | No |
| 18758081 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | June 2024 | October 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18759320 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | June 2024 | February 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18759364 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | June 2024 | December 2024 | Allow | 6 | 1 | 0 | No | No |
| 18643773 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18539946 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18539960 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18537332 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18537318 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18537342 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | June 2024 | Allow | 6 | 1 | 0 | No | No |
| 18531056 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | June 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18531095 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18388699 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | November 2023 | July 2024 | Allow | 8 | 2 | 0 | No | No |
| 18368403 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | September 2023 | July 2024 | Allow | 10 | 2 | 0 | No | No |
| 18231581 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | August 2023 | November 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 18212233 | ISOXAZOLINE COMPLEXES AND COMPOSITIONS THEREOF | June 2023 | December 2023 | Allow | 6 | 2 | 0 | Yes | No |
| 18144220 | NOVEL ISOXAZOLINE COMPLEXES AND COMPOSITIONS THEREOF | May 2023 | November 2023 | Abandon | 7 | 1 | 0 | No | No |
| 18120231 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | March 2023 | April 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18119477 | EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE | March 2023 | June 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18179283 | EMOLLIENT TOPICAL DISINFECTANTS | March 2023 | April 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18096508 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | January 2023 | August 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18075980 | MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | December 2022 | July 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18061848 | METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUG | December 2022 | January 2024 | Allow | 13 | 1 | 0 | No | No |
| 18053557 | Rucaparib particles and uses thereof | November 2022 | March 2023 | Allow | 4 | 0 | 1 | No | No |
| 18045075 | ANTI-VIRAL CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF | October 2022 | June 2025 | Allow | 32 | 2 | 1 | No | No |
| 17946243 | EXTENDED RELEASE, ABUSE DETERRENT DOSAGE FORMS | September 2022 | September 2024 | Allow | 24 | 1 | 0 | No | No |
| 17821786 | Bis-Choline Tetrathiomolybdate for Treating Wilson Disease | August 2022 | October 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17851451 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | June 2022 | March 2025 | Allow | 32 | 0 | 1 | Yes | No |
| 17851590 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION AND METHODS OF TREATMENT | June 2022 | March 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17849328 | OPHTHALMIC COMPOSITIONS AND METHODS FOR REDUCING OXIDATIVE DAMAGE TO AN EYE LENS | June 2022 | May 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17834839 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA, A DOPAMINE DECARBOXYLASE INHIBITOR AND A COMT INHIBITOR AND METHOD OF ADMINISTRATION THEREOF | June 2022 | August 2024 | Allow | 26 | 1 | 0 | No | No |
| 17804312 | CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF | May 2022 | September 2024 | Allow | 28 | 1 | 0 | No | No |
| 17775889 | INFANT FORMULA WITH SPECIAL LIPID ARCHITECTURE FOR IMPROVING POSTNATAL GROWTH OF INFANTS BORN BY CAESAREAN SECTION | May 2022 | March 2023 | Allow | 10 | 1 | 0 | No | No |
| 17729162 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | April 2022 | December 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17697084 | BIOERODIBLE DRUG DELIVERY DEVICES | March 2022 | February 2025 | Allow | 35 | 2 | 0 | No | No |
| 17691552 | Compositions and Methods for Attracting Mosquitoes and Repelling Sand Flies | March 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17687373 | ORALLY DISINTEGRATING, SUBLINGUAL AND BUCCAL FORMULATIONS | March 2022 | December 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17674042 | METHOD OF PREPARING AN ANIMAL TREAT COMPOSITION | February 2022 | September 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17665372 | DEVICE FOR CUTTING AN ANIMAL TREAT COMPOSITION | February 2022 | September 2024 | Allow | 32 | 1 | 0 | No | No |
| 17665392 | Systems and Methods for Troche Production | February 2022 | May 2025 | Allow | 39 | 2 | 1 | No | No |
| 17569047 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS | January 2022 | October 2024 | Allow | 33 | 1 | 0 | No | No |
| 17564812 | SCINTILLATOR NANOCRYSTAL-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | December 2021 | August 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17530096 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | November 2021 | March 2024 | Allow | 28 | 2 | 0 | Yes | Yes |
| 17452996 | LIQUID LOADING COMPOSITION, METHOD OF MAKING AND USE THEREOF | October 2021 | August 2024 | Allow | 33 | 1 | 0 | No | No |
| 17497393 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | October 2021 | December 2022 | Allow | 14 | 2 | 0 | Yes | No |
| 17497366 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | October 2021 | September 2022 | Allow | 11 | 2 | 1 | Yes | No |
| 17497381 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | October 2021 | December 2022 | Allow | 14 | 2 | 0 | Yes | No |
| 17442239 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | September 2021 | June 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17478117 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | September 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17475528 | SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO AN EYE COMPARTMENT | September 2021 | August 2024 | Allow | 35 | 2 | 1 | No | No |
| 17467655 | Taxane Particles and Their Use | September 2021 | February 2025 | Abandon | 41 | 2 | 0 | No | No |
| 17460476 | METHOD FOR TREATMENT OF DEPRESSION WITH ORAL DOSAGE FORMS OF KETAMINE | August 2021 | March 2025 | Allow | 42 | 3 | 0 | Yes | No |
| 17398413 | ANTI-ODOR COMPOSITIONS, STRUCTURES HAVING ANTI-ODOR CHARACTERISTICS, METHODS OF MAKING THE ANTI-ODOR COMPOSITIONS AND THE STRUCTURES | August 2021 | May 2025 | Allow | 45 | 4 | 0 | Yes | No |
| 17353149 | ORALLY DISINTEGRATING, SUBLINGUAL AND BUCCAL FORMULATIONS | June 2021 | February 2022 | Allow | 8 | 1 | 0 | Yes | No |
| 17304309 | METHOD OF INCREASING BIOAVAILABILITY AND/OR PROLONGING OPHTHALMIC ACTION OF A DRUG | June 2021 | December 2023 | Allow | 30 | 1 | 0 | No | No |
| 17347469 | Solid Oral Sulfate Salt Formulations For Cleansing A Colon And Methods Of Using Same | June 2021 | February 2022 | Allow | 8 | 1 | 0 | No | No |
| 17340973 | Solid Oral Sulfate Salt Formulations For Cleaning A Colon And Methods of Using Same | June 2021 | August 2022 | Allow | 14 | 2 | 0 | No | No |
| 17335235 | Submucosal Lifting Compositions and Methods of Same | June 2021 | March 2024 | Allow | 33 | 4 | 1 | Yes | No |
| 17298408 | ADHESIVE PAD | May 2021 | July 2025 | Allow | 49 | 3 | 0 | Yes | No |
| 17328854 | Microfluidic Extrusion | May 2021 | March 2022 | Allow | 10 | 3 | 0 | Yes | No |
| 17328633 | MICROFLUIDIC EXTRUSION | May 2021 | February 2022 | Allow | 8 | 1 | 0 | No | No |
| 17314272 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASES IN HUMAN SUBJECTS | May 2021 | December 2024 | Allow | 43 | 2 | 0 | No | No |
| 17291073 | MEDICAMENTS CONTAINING RIBOFLAVIN EXHIBITING IMPROVED FLOWABILITY | May 2021 | January 2024 | Allow | 32 | 1 | 0 | Yes | No |
| 17244158 | NITRIC OXIDE TOPICAL APPLICATION APPARATUS AND METHODS | April 2021 | January 2024 | Allow | 33 | 1 | 0 | No | No |
| 17239013 | Microfluidic Extrusion | April 2021 | October 2024 | Allow | 42 | 3 | 0 | No | No |
| 17236295 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS | April 2021 | October 2021 | Allow | 5 | 1 | 0 | Yes | No |
| 17231118 | ELAGOLIX FORMULATION | April 2021 | November 2021 | Allow | 7 | 2 | 0 | Yes | No |
| 17219039 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME | March 2021 | May 2023 | Allow | 26 | 3 | 0 | No | No |
| 17203687 | COMPOSITIONS AND METHODS FOR TREATING CROHN'S DISEASE AND RELATED CONDITIONS AND INFECTIONS | March 2021 | November 2023 | Allow | 32 | 1 | 0 | Yes | No |
| 17201811 | Anticancer Compositions | March 2021 | October 2023 | Allow | 31 | 1 | 0 | No | No |
| 17194780 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | March 2021 | September 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 17188655 | METHODS AND COMPOSITIONS TO MODULATE THE GUT MICROBIOTA AND TO MANAGE WEIGHT | March 2021 | August 2021 | Allow | 5 | 1 | 0 | Yes | No |
| 17182093 | POLYHYDROXY FULLERENE SUNSCREEN ACTIVE AGENTS AND COMPOSITIONS | February 2021 | December 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17180256 | METHODS AND COMPOSITIONS TO MODULATE THE GUT MICROBIOTA AND TO MANAGE WEIGHT | February 2021 | August 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17178117 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | February 2021 | October 2024 | Allow | 44 | 1 | 1 | No | No |
| 17263710 | PELLETS HAVING A MULTI-LAYER STRUCTURE FOR DELAYED RELEASE OF THE ACTIVE SUBSTANCE IN THE DISTAL COLON | January 2021 | July 2021 | Allow | 6 | 1 | 0 | No | No |
| 17137713 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME | December 2020 | August 2021 | Allow | 7 | 2 | 0 | No | No |
| 17257076 | USE OF PRUSSIAN BLUE NANOPARTICLES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION, DELAY OR TREATMENT OF NEURODEGENERATIVE DISEASE | December 2020 | March 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17108895 | CROMOLYN COMPOSITIONS AND METHODS THEREOF | December 2020 | February 2021 | Allow | 2 | 0 | 0 | No | No |
| 17101706 | CONTROLLED-RELEASE SYSTEM OF ACTIVE PHARMACEUTICAL INGREDIENT AND PREPARATION METHOD THEREFOR | November 2020 | October 2023 | Allow | 35 | 1 | 0 | No | No |
| 17099663 | SCINTILLATOR NANOCRYSTAL-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | November 2020 | September 2021 | Allow | 10 | 2 | 0 | No | No |
| 17055640 | TRANSDERMAL DRUG DELIVERY PATCH AND MANUFACTURING METHOD THEREOF | November 2020 | July 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17055139 | A NEW USE OF THE POLOXAMER AS A PHARMACOLOGICALLY ACTIVE SUBSTANCE | November 2020 | February 2025 | Allow | 51 | 4 | 0 | No | No |
| 17055065 | COMPOSITIONS COMPRISING PGI2-RECEPTOR AGONISTS AND PROCESSES FOR THE PREPARATION THEREOF | November 2020 | May 2025 | Allow | 54 | 3 | 0 | No | No |
| 17081512 | Methods for Formulating an API, Composite Materials, and Solid Unit Dosage Forms | October 2020 | June 2024 | Abandon | 43 | 4 | 1 | No | No |
| 17075656 | Methods of Administering Cannabinoid to People Diagnosed With HIV | October 2020 | October 2022 | Allow | 24 | 2 | 0 | No | No |
| 17048306 | MEDICAL DRESSING MATERIAL HAVING CHITOSAN FABRIC SPONGE STRUCTURE AND METHOD OF MANUFACTURING SAME | October 2020 | July 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17047428 | APIXABAN FORMULATIONS | October 2020 | October 2023 | Allow | 36 | 2 | 0 | No | No |
| 17046107 | MULTIPARTICULATE SOLID DOSAGE FORM HAVING AN ELASTIC TEXTURE | October 2020 | August 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17065981 | ANTI-VIRAL CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF | October 2020 | July 2022 | Allow | 21 | 2 | 1 | Yes | No |
| 17044698 | TABLET COMPOSITIONS COMPRISING ABIRATERONE ACETATE | October 2020 | September 2023 | Allow | 35 | 1 | 0 | Yes | No |
| 17030705 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | September 2020 | May 2024 | Allow | 44 | 2 | 0 | Yes | No |
| 17027567 | IBUDILAST ORAL FORMULATIONS AND METHODS OF USING SAME | September 2020 | September 2023 | Allow | 35 | 1 | 1 | No | No |
| 16982399 | PHARMACEUTICAL COMPOSITION COMPRISING META ARSENITE AND METHOD OF MANUFACTURE | September 2020 | November 2024 | Allow | 50 | 3 | 0 | No | No |
| 17023635 | Taxane Particles and Their Use | September 2020 | February 2021 | Allow | 5 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SASAN, ARADHANA.
With a 36.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SASAN, ARADHANA works in Art Unit 1615 and has examined 1,114 patent applications in our dataset. With an allowance rate of 63.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner SASAN, ARADHANA's allowance rate of 63.7% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SASAN, ARADHANA receive 2.06 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SASAN, ARADHANA is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +23.5% benefit to allowance rate for applications examined by SASAN, ARADHANA. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 27.4% of applications are subsequently allowed. This success rate is in the 37% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 44.8% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 71.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 56% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 78.2% of appeals filed. This is in the 66% percentile among all examiners. Of these withdrawals, 63.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 42.1% are granted (fully or in part). This grant rate is in the 43% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 3.0% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.7% of allowed cases (in the 63% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.